VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	127M 113M 104M 94.68M 178M 11.89B 184M 1.25B 499M 6.35B 475M 465M 20.04B	P/E 2026 *	-8.76x	P/E 2027 *	-7.78x
Enterprise Value	127M 113M 104M 94.68M 178M 11.89B 184M 1.25B 499M 6.35B 475M 465M 20.04B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

11-06	Guggenheim Initiates Coverage on Yarrow Bioscience With Buy Rating, $60 Price Target	MT
09-14	Yarrow Bioscience Closes $172.5 Million Public Offering	MT
09-10	Yarrow Bioscience Launches Public Offering of Common Stock	MT
08-13	Yarrow Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN
08-03	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
07-29	RTW Biotech's Portfolio Company Completes Merger with Vyne Therapeutics	MT
07-27	Yarrow Bioscience, Inc.(NasdaqCM:YARW) added to NASDAQ Composite Index	CI
07-27	Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.	CI
07-27	Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101	MT
07-26	Yarrow Bioscience, Inc. announced that it has received $200 million in funding from a group of investors	CI
07-24	Top Premarket Decliners	MT
07-21	VYNE Approves 1-for-50 Reverse Stock Split	MT

11-06	Guggenheim Initiates Coverage on Yarrow Bioscience With Buy Rating, $60 Price Target	MT
08-03	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
25-07-31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
24-11-18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
23-05-12	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT

11-02	Yarrow Bioscience Announces Participation in November Investor Events	BU
09-14	Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	BU
09-10	Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering	BU
09-10	Yarrow Bioscience Announces Proposed Underwritten Public Offering	BU
08-13	Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	19.05M
WUXI APPTEC CO., LTD.	-4.83%	+2.88%	+55.87%	+69.12%	69.4B
ARGENX SE	+0.02%	+1.42%	+12.77%	+75.21%	57.24B
LONZA GROUP AG	-1.34%	+3.53%	+23.22%	+101.58%	57.62B
IQVIA HOLDINGS INC.	+2.62%	-1.17%	+29.37%	+37.84%	43.65B
BEONE MEDICINES AG	+5.09%	+9.53%	+26.62%	+121.44%	44.03B
REVOLUTION MEDICINES, INC.	+8.24%	+1.06%	+224.03%	+767.69%	38.08B
CELLTRION, INC.	-1.86%	+11.46%	+26.67%	+61.40%	36.31B
GENMAB A/S	-2.97%	-6.89%	+91.79%	+74.60%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+5.68%	+36.21%	-0.69%	25.47B
Average	+0.28%	+2.24%	+58.51%	+145.36%	44.93B
Weighted average by Cap.	+0.05%	+2.44%	+53.94%	+138.05%

Foamix Pharmaceuticals Ltd. Stock Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news: Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

	2026 *	2027 *
Net sales	-	-
Net income	-38.54M -34.57M -31.59M -28.84M -54.34M -3.62B -56.05M -381M -152M -1.93B -145M -142M -6.1B	-66.89M -60M -54.83M -50.05M -94.31M -6.29B -97.28M -661M -264M -3.36B -251M -246M -10.59B
Net Debt	-	-